Veru Q4 2023 Earnings Report $0.71 0.00 (0.00%) (As of 12:56 PM ET) Earnings HistoryForecast Veru EPS ResultsActual EPS-$0.16Consensus EPS -$0.20Beat/MissBeat by +$0.04One Year Ago EPSN/AVeru Revenue ResultsActual Revenue$3.86 millionExpected Revenue$3.95 millionBeat/MissMissed by -$90.00 thousandYoY Revenue GrowthN/AVeru Announcement DetailsQuarterQ4 2023Date12/8/2023TimeN/AConference Call ResourcesPress ReleaseVERU Earnings HistoryPowered by Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Veru Earnings HeadlinesUS Penny Stocks To Consider In December 2024December 16 at 1:28 PM | finance.yahoo.comThe past three years for Veru (NASDAQ:VERU) investors has not been profitableDecember 11, 2024 | finance.yahoo.comDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.December 18, 2024 | Brownstone Research (Ad)Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting DisordersNovember 26, 2024 | globenewswire.comGroup hopes bleed-kit project will save livesNovember 13, 2024 | bbc.comLifesaving kits to be rolled out across Bedfordshire to help people with critical bleedsNovember 13, 2024 | msn.comSee More Veru Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email. Email Address About VeruVeru (NASDAQ:VERU), a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.View Veru ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
